Please ensure Javascript is enabled for purposes of website accessibility

Why Tilray Stock Is Rising Today

By Joe Tenebruso - Mar 10, 2021 at 11:17AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The cannabis producer is entering a new market.

What happened

Shares of Tilray (TLRY) climbed on Wednesday after the marijuana company announced it had received regulatory approval to sell medical cannabis products in New Zealand. 

As of 11 a.m. EST, Tilray's stock was up more than 3% after rising as much as 11% earlier in the day.

So what

Tilray's approval represents the first under the New Zealand Ministry of Health and the Medicinal Cannabis Agency's new system that's designed to make it easier and less expensive for patients to obtain cannabis products that satisfy its quality standards.

A doctor is holding a cannabis leaf.

Tilray is helping doctors provide medical cannabis to those in need. Image source: Getty Images.

"As medical cannabis regulations continue to progress around the world, we're incredibly honored to be recognized as a trusted partner in offering the highest-quality medical cannabis products," Tilray CEO Brendan Kennedy said in a press release. "We are grateful to partner with New Zealand's Ministry of Health and the Medicinal Cannabis Agency to improve access for patients in need across the country."

Tilray will initially focus on supplying its Purified CBD (cannabidiol) products to New Zealand's hospitals and pharmacies. It intends to offer a broader range of cannabis products later this year.

Now what

As it progresses toward its impending merger with Aphria (APHA), successful international expansion will remain an important growth driver for Tilray. The combined company should be a powerful force within the global cannabis market, with more projected revenue than any other company. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tilray Stock Quote
Aphria Stock Quote

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.